


SUPPORT CLINICAL TRIAL ACCESS FOR MEDICAID RECIPIENTS

SUPPORT SB2499 (SEN. MANAR)/ HB4314 (REP. LILLY)

- Clinical trials are critical to advancing life-saving cancer treatments. Patient participation in trials is crucial to this success. Currently the Medicaid program is one of the few remaining insurance programs in the U.S. that is not required to cover routine care for patients in cancer clinical trials. Although several states require Medicaid plans to offer this coverage, Illinois is not one of them.



Medicaid is the second largest source of insurance in Illinois and covers more than one in five residents. Source: Kaiser Family Foundation

- More than 20% of Illinoisans are covered by Medicaid, the second largest type of insurance behind Medicare. The program serves children, disabled adults, lower income adults, and seniors. 36% of Illinois children are enrolled in Medicaid. Children who face critical illnesses and diseases deserve access to clinical trials .
- Because routine costs would be paid for by Medicaid if the patient were not on a clinical trial, it is generally assumed that there is no or minimal cost differential for Medicaid to cover these costs within a clinical trial.
- Participants in cancer clinical trials often do not reflect the broader population diagnosed with cancer. The elderly, minorities, and those with lower incomes tend to be underrepresented in clinical trials. In fact, individuals with household incomes below \$50,000 are nearly 30% less likely to enroll in a clinical trial.
- Because Medicaid beneficiaries tend to be lower income and more diverse, ensuring their participation in clinical trials makes it more likely that new therapies will be tested in a representative population.

SUPPORTERS OF SB2499 (SEN.MANAR)/ HB4314 (REP. LILLY)



For more information, please contact Shana Crews at shana.crews@cancer.org or 309.645.6909